Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced NSCLC
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2017
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 16 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.